The clinical relevance of HMOs in infants with CMPA

Professor Vandenplas provided an overview of risk factors for cow’s milk protein allergy (CMPA) in infants and highlighted the two components of breast milk that play a major role in delivering immune support. He also focused on extensive hydrolysed formulas, which are considered the first-choice option in the management of CMPA. Specifically, Prof. Vandenplas reviewed clinical data that support the addition of human milk oligosaccharides (HMOs) to these speciality formulas. This included an assessment of data from the recent multicentre PLATYPUS study, which evaluated the tolerance, safety, and growth efficacy of amino acid-based formulas supplemented with HMOs in infants with moderate-to-severe CMPA.